Beam Therapeutics Margen de beneficio
¿Qué es el Margen de beneficio de Beam Therapeutics?
El Margen de beneficio de Beam Therapeutics Inc. es -35.09%
¿Cuál es la definición de Margen de beneficio?
El margen de ganancia es una medida de la rentabilidad. La misma se calcula al encontrar la ganancia neta como un porcentaje de los ingresos.
Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.
Margen de beneficio de compañías en Sector Health Care en NASDAQ en comparadas con Beam Therapeutics
¿Qué hace Beam Therapeutics?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Empresas con margen de beneficio similar a Beam Therapeutics
- Raunaq EPC International tiene Margen de beneficio de -35.31%
- Hempstract tiene Margen de beneficio de -35.31%
- Mobecom tiene Margen de beneficio de -35.25%
- China Merchants Commercial Real Estate Investment Trust tiene Margen de beneficio de -35.23%
- Cambium Networks Corp tiene Margen de beneficio de -35.16%
- E-Land Apparel tiene Margen de beneficio de -35.10%
- Beam Therapeutics tiene Margen de beneficio de -35.09%
- Suncity tiene Margen de beneficio de -35.09%
- The Motor & General Finance tiene Margen de beneficio de -35.06%
- Inox Leisure tiene Margen de beneficio de -35.01%
- PopReach tiene Margen de beneficio de -34.99%
- Brooks Laboratories tiene Margen de beneficio de -34.98%
- Paramount Inc tiene Margen de beneficio de -34.97%